Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Sorrento Therapeutics, Inc.
This is a Phase 2a randomized, placebo-controlled multicenter study designed to investigate the efficacy, safety and tolerability of COVI-MSC in treating post COVID-19 "long haul" pulmonary compromise.
COVI-MSC will be administered intravenously on Day 0, Day 2, and Day 4.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Has had prior laboratory-confirmed SARS-CoV-2 infection as determined by an approved polymerase chain reaction (PCR) or an approved antigen test of any specimen
Has had a recent (within a week) negative SARS-CoV-2 test (an approved PCR or antigen test)
Has had at least moderate or severe post-COVID-19 pulmonary symptoms for at least 3 months which have resulted in reduced physical functioning compared to pre-COVID-19 status
Willing to follow contraception guidelines
You may not be if
Clinically improving pulmonary status over the month prior to screening
Undergone a previous stem cell infusion unrelated to this trial
Pregnant or breast feeding or planning for either during the study
Suspected uncontrolled active bacterial, fungal, viral, or other infection
Any significant medical condition, laboratory value or other illness that in the investigator's opinion would interfere or prevent safe participation in the study
History of a splenectomy, lung transplant or lung lobectomy
Concurrent participation in another clinical trial involving therapeutic interventions (observational study participation is acceptable)
